Certara Inc   (CERT)
Other Ticker:  
    Sector  Technology    Industry Software & Programming
   Industry Software & Programming
   Sector  Technology
Price: $15.9300 $-0.28 -1.727%
Day's High: $16.345 Week Perf: -8.66 %
Day's Low: $ 15.83 30 Day Perf: -12.81 %
Volume (M): 610 52 Wk High: $ 24.70
Volume (M$): $ 9,722 52 Wk Avg: $17.10
Open: $16.24 52 Wk Low: $11.81

 Market Capitalization (Millions $) 2,536
 Shares Outstanding (Millions) 159
 Employees 1,114
 Revenues (TTM) (Millions $) 353
 Net Income (TTM) (Millions $) -34
 Cash Flow (TTM) (Millions $) 59
 Capital Exp. (TTM) (Millions $) 14

Certara Inc
We expedite medicines to patients by transforming traditional drug research and development using biosimulation software, technology, and services.
Biosimulation is a sophisticated technique that allows virtual trials to be conducted using virtual patients in order to better understand how medications respond in various persons. Throughout drug research and development, biopharmaceutical firms utilize our patented biosimulation software to guide important decisions that not only save substantial time and money but also increase drug safety and efficacy, benefitting millions of lives each year.
We build our biosimulation technology on first principles of biology, chemistry, and pharmacology with proprietary mathematical algorithms that model how medicines and diseases behave in the body. For over two decades, we have honed and validated our biosimulation technology with an abundance of data from scientific literature, lab research, and preclinical and clinical studies. In turn, our customers use biosimulation to conduct virtual trials to answer critical questions, such as: What will be the human response to a drug based on preclinical data' How will other drugs interfere with this new drug' What is a safe and efficacious dose for children, the elderly, or patients with pre-existing conditions' Virtual trials may be used to optimize dosing on populations that are otherwise difficult to study for ethical or logistical reasons, such as infants, pregnant women, the elderly, and cancer patients.
We believe that biosimulation continues to grow in adoption, driven by increasing global regulatory support and advancements in technology. We believe we are well-positioned to capture the significant market opportunity ahead of us. Our growth strategy is to build out the depth and breadth of our scalable, end-to-end biopharmaceutical platform to advance all stages of the continuum, from discovery and development to regulatory submission and market access. We continue to innovate and introduce new functionality and uses of biosimulation and technology-driven solutions. We increasingly integrate the science and data we obtain across this end-to-end platform to inform critical decisions. We further reduce the cost and time of human trials to materially accelerate the speed of development and availability of therapies to patients worldwide. As exciting, new research areas arise, we attract and hire specialized talent and acquire businesses to expand our offerings to address these market opportunities.

With continued innovation in and adoption of our biosimulation software, technology and services, we believe more biopharmaceutical companies worldwide will leverage more of our end-to-end platform to reduce cost, accelerate speed to market, and ensure safety and efficacy of medicines for all patients.

Biosimulation: Biosimulation is the mathematical modeling of biological processes and systems to simulate how a drug affects the body, how the body affects the drug, how potential doses will affect different patient groups, and how patients will respond under various clinical scenarios. Biosimulation informs every stage of the drug discovery and development process and brings value through:
Identifying potential winners and losers at an earlier stage and allowing programs to 'fail faster;'
Streamlining preclinical and clinical studies or eliminating certain ones altogether;
Optimizing dosing for different populations for enhanced safety and efficacy; and
Increasing probability of success and return on R&D, amongst others.
Regulatory Science: Regulatory science is the development and application of scientific methods, tools, and approaches to support regulatory and other policy objectives. Expert management of these processes is critical to drugs receiving regulatory approval and ultimately reaching patients and generating sales. Providers of regulatory technology and expertise drive significant value for biopharmaceutical companies through:
Utilizing best-in-class technology to reduce time-intensive regulatory writing activities and the need for regulatory writing staff;
Managing submission timelines and other requirements of global regulatory agencies;
Generating clear, accurate applications and submissions; and
Developing comprehensive global regulatory strategies, amongst others.
Market Access: To achieve commercial access, sponsors must assess, optimize and persuasively communicate the value of a new therapy, both therapeutic and economic, that stakeholders such as payors and health care providers will accept and act on. Market access services, including real-world evidence and health economics outcomes research, generate value by:
Creating cost and comparative effectiveness models to support pricing and payor reimbursement;
Analyzing payor needs and using economic models to develop contracting strategies that optimize value; and
Collecting and analyzing real-world data for use in market and payor communications, amongst others. We believe that our end-to-end platform is well-positioned to continue benefiting from market trends. In addition to continued growth in our core markets, we expect to capture a broader share of overall biopharmaceutical R&D spend as we continue to innovate and add new solutions to our end-to-end platform.
Our Competitive Strengths
We compete by offering a broad and deep combination of industry-standard biosimulation software and technology-driven services across all stages of the continuum, from discovery and development to regulatory approval and market access. We have cultivated the following competitive strengths for more than two decades:
Our Proprietary, Scalable Biosimulation Software
Our proprietary, scalable biosimulation software, built on first principles integrates biosimulation models, scientific knowledge, and data, which we believe would require years of effort, immense resources, and scarce expertise to duplicate. Our versatile biosimulation software is deployed to public and private cloud networks, on-premises, and data centers. Scientists can run multiple simulation projects on a cloud compute platform or internal clusters. We protect our proprietary technology through intellectual property rights, including copyrights, patents, trade secrets, know-how, and trademarks.

   Company Address: 100 Overlook Center Princeton 8540 NJ
   Company Phone Number: 716-7900   Stock Exchange / Ticker: NASDAQ CERT

Customers Net Income grew by CERT's Customers Net Profit Margin grew to

31.68 %

36.63 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABCL   -7.42%    
BRKR   -9.32%    
MASS   -3.63%    
SDGR   -4.89%    
SLP   -1.18%    
• View Complete Report

Merger and Acquisition

Certara-Applied BioMath Merger: Creating a New Frontier in Biosimulation for Optimal Therapies' Dosing

Published Wed, Dec 13 2023 9:30 PM UTC

In a recent press release, Certara Inc, a renowned global leader in biosimulation, announced its acquisition of Applied BioMath, marking a significant expansion of its biosimulation portfolio. This strategic move aims to industrialize cutting-edge capabilities for optimal dosing of novel therapies. With this acquisition, the newly formed Certara-Applied BioMath org...

Product Service News

Revolutionizing Drug Formulation and Development: Certara's Simcyp Software Leads the Way in Efficiency and Cost-Effectiveness

Published Tue, Nov 21 2023 9:30 PM UTC

Increasing Efficiency and Performance in Drug Formulation and Development: Certara's Simcyp Biopharmaceutics Software
Certara Inc, a leading drug research and development company, has introduced the Simcyp Biopharmaceutics software, aimed at revolutionizing drug formulation and development processes. By utilizing this innovative software, biopharmaceutic, formulation, an...

Certara Inc

Certara Inc Faces Unexpected Loss Despite Revenue Growth in the Third Quarter of 2023 Earnings Season

Certara Inc, a Software & Programming company, experienced a disheartening third quarter in 2023, facing a notable shortfall in earnings per share and witnessing a decline in revenue. Despite a slight growth in revenue when compared to the previous year, Certara Inc fell short in delivering promising results compared to its industry contemporaries. Additionally, the company reported a substantial net shortfall instead of the anticipated net income. This article aims to provide an in-depth analysis of Certara Inc's recent financial performance and outline the potential reasons behind its bearish outlook.
Earnings and Revenue Decline:
In the third quarter of 2023, Certara Inc experienced a significant decline in earnings per share, falling from $0.03 per share in the previous financial reporting period to a shortfall of $-0.31 per share. This decline is even more pronounced when compared to the earnings of $0.02 per share from a year ago. This downward trend in earnings per share raises concerns about Certara Inc's ability to generate profits and meet investor expectations.

Certara Inc

Certara Inc. Records Impressive 9.292% Surge in Revenue During Recent Fiscal Period

Certara Inc, a notable player in the Software & Programming industry, recently released its financial report for the April to June 30, 2023, period. The company displayed resilience and growth, as indicated by its impressive earnings per share (EPS) and increased revenue. Let's delve into the interesting facts and figures from Certara Inc's latest financial interval.
Rising Earnings per Share:
Certara Inc's EPS remained steady at $0.03 per share, compared to zero earnings per share the previous year. This indicates stable financial performance and signifies the company's ability to maintain profitability amid challenging market conditions. Notably, the company witnessed a 200% increase in EPS from $0.01 per share in the preceding reporting period.

Certara Inc

Certara Inc defies expectations with impressive revenue surge of 10.729% in Q1 2023

Certara Inc faces a bleak future ahead as it experienced a significant drop in its earnings per share (EPS) in the January to March 31, 2023 period. The company reported that its EPS remained unchanged at $0.01 per share from the same reporting season a year prior, while it experienced a massive decline of -81.17% from $0.05 per share from the prior reporting season.
Moreover, the company's net earnings of $1.358 million in the same reporting period plummeted by -38.55% from $2.210 million in the corresponding period a year before. This significant drop in earnings is a major red flag for investors, as it indicates that there may be serious issues that the company is facing.


Certara Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com